

Taori Sandeep & Associates

CHARTERED ACCOUNTANTS

Br. Office: Flat No. 201, Nav Sudhir CHS Ltd, 113 Tilak Nagar, MG Road No. 6, Goregaon West, Mumbai 400 104. Mob. 7021416997, 07738364419 Email- cpatul14@gmail.com

Head Office: "Deepa Lakshmi", 106, Kherapati Colony, Gwalior- 474002 (M.P.)

INDEPENDENT AUDITOR'S REPORT ON QUARTERLY FINANCIAL RESULTS AND YEAR TO DATE RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

To,
The Board of Directors
Remedium Lifecare Limited
(formerly known as Roxy Exports Limited)
6th/01, Hyde Park, CTS No. 680 Saki Vihar Road, Saki Naka,
Mumbai- 400072.

Opinion

We have audited the accompanying annual financial results of **Remedium Lifecare Limited (formerly known as Roxy Exports Limited)** (hereinafter referred to as the "Company") for the year ended 31 March 2022, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid annual financial results:

- are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and
- give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information for the year ended 31 March 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules there-under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence, we have obtained, is sufficient and appropriate to provide a basis for our opinion.

Management's and Board of Directors' Responsibilities for the Annual Financial Results

These annual financial results have been prepared on the basis of the annual financial statements. The Company's Management and the Board of Directors are responsible for the preparation and presentation of these annual financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting



Taori Sandeep & Associates

CHARTERED ACCOUNTANTS

Br. Office: Flat No. 201, Nav Sudhir CHS Ltd, 113 Tilak Nagar, MG Road No. 6, Goregaon West, Mumbai 400 104. Mob. 7021416997, 07738364419 Email- cpatul14@gmail.com

Head Office: "Deepa Lakshmi", 106, Kherapati Colony, Gwalior- 474002 (M.P.)

policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records relevant to the preparation and presentation of the annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process

Auditor's Responsibilities for the Audit of the Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.



Taori Sandeep & Associates

CHARTERED ACCOUNTANTS

Br. Office: Flat No. 201, Nav Sudhir CHS Ltd, 113 Tilak Nagar, MG Road No. 6, Goregaon West, Mumbai 400 104. Mob. 7021416997, 07738364419 Email- cpatul14@gmail.com

Head Office: "Deepa Lakshmi", 106, Kherapati Colony, Gwalior- 474002 (M.P.)

- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matters

The standalone annual financial results include the results for the quarter ended 31 March 2022 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us, as required under the Listing Regulations.

For TAORI SANDEEP & ASSOCIATES
Chartered Accountants
Firm Registration No. : 007414C



A handwritten signature in blue ink, appearing to read "Atul".

CA Atul Jain
(Partner)
M. No. : 048920

Place: Mumbai
Date: 30.05.2022
UDIN: 22048920AJYAUX3768

REMEDIUM LIFECARE LIMITED
(Formerly Known as "Roxy Exports Limited")
REGD. OFFICE: 6th/01, Hyde Park, CTS No. 680, Saki Vihar Rd, Saki Naka, Mumbai - 400072
E-mail: info@remediumlifecare.com;
CIN: L24100MH1988PLC343805

Statement of Standalone Audited Financial Results for the Quarter and Year ended March 31, 2022


(₹ in Lakhs)

Particulars	Quarter Ended			Year Ended	
	31st March, 2022	31st Dec, 2021	31st March, 2021	31st March, 2022	31st March, 2021
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
I. Revenue from Operations	4028.84	20604.98	5585.48	50479.19	9003.39
II. Other Income	0.00	0.00	0.20	0.00	0.20
III. Total Income (I+II)	4028.85	20604.98	5585.68	50479.19	9003.59
IV. Expenses					
Cost of Material Consumed	3926.36	20384.69	5488.76	49846.98	8773.94
Purchases of Stock-in-trade	0.00	0.00	0.00	0.00	0.00
Changes in inventories of finished goods, Work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00
Employee Benefits Expenses	15.97	16.48	7.80	53.32	18.80
Finance Costs	10.70	0.00	0.00	10.70	0.00
Depreciation and amortisation expenses	1.98	1.96	1.80	7.38	8.01
Other Expenses	145.45	133.18	41.76	408.30	139.56
Total Expenses (IV)	4100.46	20536.30	5539.33	50326.69	8938.31
V. Profit/(Loss) before exceptional items and tax (III- IV)	-71.61	68.68	45.75	152.51	65.29
VI. Exceptional items			0.00	0.00	0.00
VII. Profit/(Loss) before tax (V-VI)	-71.61	68.68	45.75	152.51	65.29
VIII. Tax Expense					
(1) Current tax	45.06	0.00	17.27	45.06	17.27
(2) Deferred tax	-0.33	0.00	-0.04	-0.33	-0.04
(3) Previous Year Tax	0.00	0.00	0.00	0.00	0.00
Total Tax	44.73	0.00	17.24	44.73	17.24
IX. Profit/(Loss) for the period from continuing operations (VII-VIII)	-116.35	68.68	28.52	107.78	48.05
X. Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00
XI. Tax expense of discontinued operations	0.00	0.00	0.00	0.00	0.00
XII. Profit/(Loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00
XIII. Profit/(Loss) for the period (IX+XII)	-116.35	68.68	28.52	107.78	48.05
XIV. Other Comprehensive Income	0.00	0.00	0.00	0.00	0.00
(A) (i) Items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will not be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
(B) (i) Items that will be classified to profit or loss	0.00	0.00	0.00	0.00	0.00
(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00
XV. Total Comprehensive Income for the period (XIII+XIV)	-116.35	68.68	28.52	107.78	48.05
(Comprising Profit (Loss) and Other Comprehensive Income for the Period)					
XVI. Earnings per equity share (for continuing operation):					
(1) Basic	0.00	0.00	0.00	0.00	0.00
(2) Diluted	0.00	0.00	0.00	0.00	0.00
XVII. Earnings per equity share (for discontinued operation):					
(1) Basic	0.00	0.00	0.00	0.00	0.00
(2) Diluted	0.00	0.00	0.00	0.00	0.00
XVIII. Earnings per equity share (for discontinued & continuing operations)					
(1) Basic	0.00	0.00	0.00	0.00	0.00
(2) Diluted	0.00	0.00	0.00	0.00	0.00

Notes:

- The above results have been reviewed by Audit Committee and taken on record by the Board of Directors at its Meeting held on May 30, 2022. The Statutory Auditors have carried out their audit for the above results.
- The above results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS), prescribed under section 133 of the Companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The IND AS compliant corresponding figures for the period as reported above have not been subjected to review. However, the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- The figures for the previous period/year have been regrouped/reclassified, wherever necessary, to conform to the current period/year classification.
- As the Company's business activity falls within a single segment, therefore "Segment Reporting" is not applicable.
- Figures of the quarter ended 31st March, 2022 and 31st March, 2021 are balancing figures between audited figures in respect of full financial year and the year to date figures upto third quarter of the relevant financial year which were subject to limited review by the auditors.

For Remedium Lifecare Limited



VILAS LOKHANDE
(Whole Time Director)
DIN : 01228041

Date: 30.05.2022
Place : Mumbai



REMEDIUM LIFECARE LIMITED

(Formerly Known as "Roxy Exports Limited")

REGD. OFFICE: 6th/01, Hyde Park, CTS No. 680, Saki Vihar Rd, Saki Naka, Mumbai - 400072

E-mail: info@remediumlifecare.com;

CIN: L24100MH1988PLC343805

Statement of Standalone Assets and Liabilities

(₹ in Lakhs)


Particulars	As at 31st March, 2022	As at 31st March, 2021
	(Audited)	(Audited)
ASSETS		
Non current assets		
(a) Property, Plant and Equipment	8.54	7.30
(b) Capital Work in Progress	-	-
(c) Investment Property	-	-
(d) Goodwill	-	-
(e) Other Intangible Assets	-	-
(f) Intangible assets under development	10.08	13.70
(g) Biological Assets other than bearer plants	-	-
(h) Financials Assets-		
(i) Investments	-	-
(ii) Trade Receivables	-	-
(iii) Loans	-	-
(iv) Other(to be specified)	-	-
(i) Deferred tax assets (net)	-	-
(j) Other non-current assets	-	-
Sub-total Non Current Assets	18.61	21.01
Current Assets		
(a) Inventories	8,387.33	310.82
(b) Financials Assets		
(i) Investments	-	-
(ii) Trade receivables	6,399.60	2,368.44
(iii) Cash and cash equivalents	69.80	66.31
(iv) Bank Balance other than (iii) above	73.77	14.77
(v) Loans/Advances	7,410.94	1,059.49
(vi) Others (to be specified)	15.59	12.52
(c) Current tax Assets	-	-
(d) Other current Assets	-	-
Sub-total - Current Assets	22,357.01	3,832.35
TOTAL ASSETS	22,375.63	3,853.36



P.T.O.

EQUITY AND LIABILITIES		
Equity-		
(a) Equity Share Capital	360.00	360.00
(b) Other Equity	133.82	25.77
Sub Total Equity	493.82	385.77
Liabilities		
Non -Current Liabilities		
(a) Financials Liabilities		
(i) Borrowings	-	1,050.14
(ii) Trade Payable	-	-
(iii) Other Financial liabilities (other than specified in item (b) to be specified	-	-
(b) Provisions	-	-
(c) Deffered Tax Liabilites (net)	0.01	0.34
(d) Other Non-Current Liabilities	-	-
Sub Total Non Current Liabilities	0.01	1,050.48
Current Liabilities		
(a) Financials Liabilities	-	-
(i) Borrowings	-	-
(ii) Trade Payables	12,456.28	2,377.23
(iii) Other Financial liabilities (other than specified in item (c) to be specified	-	-
(b) Other current liabilities	9,378.95	38.38
(c) provisions	46.56	1.50
(d) Current Tax Liabilities	-	-
Sub Total Non Current Liabilities	21,881.80	2,417.11
TOTAL EQUITY AND LIABILITIES	22,375.63	3,853.36

For REMEDIUM LIFECARE LIMITED



VILAS LOKHANDE
(WHOLE TIME DIRECTOR)
DIN : 01228041
Date: 30.05.2022
Place : Mumbai



REMEDIUM LIFECARE LIMITED
(Formerly Known as "Roxy Exports Limited")
REGD. OFFICE: 6th/01, Hyde Park, CTS No. 680, Saki Vihar Rd, Saki Naka, Mumbai - 400072
E-mail: info@remediumlifecare.com;
CIN: L24100MH1988PLC343805

Standalone Cashflow Statement for the Year ended on 31st March,2022

(₹ in Lakhs)

<u>Particulars</u>	LF	<u>As at 31.03.2022</u>		<u>As at 31.03.2021</u>	
		<u>Amount (Rs)</u>	<u>Amount (Rs)</u>	<u>Amount (Rs)</u>	<u>Amount (Rs)</u>
<u>A. Cashflow from operating activity</u>					
Net Profit / (Loss) before extraordinary items and tax		152.51		65.29	
<u>Adjustments for:</u>					
Depreciation and amortisation		7.38		6.01	
Profit on sale of FA		-		-	
Finance Cost		10.70		-	
Interest Income		-		-	
Operating profit / (loss) before working capital changes			170.58		71.29
<u>Changes in working capital:</u>					
<u>Adjustments for (increase) / decrease in operating assets:</u>					
Inventories		-8,076.51		-240.70	
Trade receivables		-4,031.16		-2,218.45	
Other Current assets		-3.07		0.21	
Current Loans and Advances		-6,351.44		-981.13	
Non Current Loans		-		-	
<u>Adjustments for increase / (decrease) in operating liabilities:</u>					
Trade payables		10,079.06		2,338.54	
Other current liabilities		9,340.57		12.75	
Current provisions		45.06		-	
Current Tax liabilities		-		-	
Cashflow from extraordinary activity					
Cash Generated from operation			1,173.09		-1,017.49
Net Income tax paid			-44.79		-3.77
<u>Net cash flow from / (used in) operating activities(A)</u>			1,128.30		-1,021.25
<u>B. Cash flow from investing activities</u>					
Capital expenditure on fixed assets, including capital advances		-4.98		-3.89	
Proceeds from sale of fixed assets		-		-	
Receipt of Loans & Advances		-		-	
Interest received		-		-	
— Others		-		-	
Cash flow from extraordinary items					
Net cash flow from / (used in) investing activities (B)			-4.98		-3.89
<u>C. Cash flow from financing activities</u>					
Proceeds from issue of equity shares		-		-	
Proceeds from long-term borrowings		-		-	



P.T.O.

Finance cost	-10.70	-	
Loan From Director	-1,050.14	1,013.71	
Dividends paid	-	-	
Tax on dividend	-	-	
Net cash flow from / (used in) financing activities (C)	-1,060.84		1,013.71
Net Cash flow during the period	62.48		-11.44
Cash and cash equivalents at the beginning of the year	81.08		92.52
Cash and cash equivalents at the end of the year	143.56		81.08
Reconciliation of Cash and cash equivalents with the Balance Sheet:			
Cash and cash equivalents as per Balance Sheet	143.56		81.08
Less: Bank balances not considered as Cash and cash equivalents as defined in AS 7 "Statements of Cash Flow"			
Net Cash and cash equivalents as defined in AS 7 ("Statement of Cash Flows")	143.56		81.08
Add: Current investments considered as part of Cash and cash equivalents (as defined in Ind AS 7 ("Statement of Cash Flows")) (Refer Note (ii) to Note 16 Current investments)			
Cash and cash equivalents at the end of the year *	143.56		81.08
* Comprises			
(a) Cash on hand	23.92		66.31
(b) Cheques, drafts on hand	45.88		
(c) Balances with banks			
(i) In current accounts	73.77		14.77
(ii) In EEFC accounts	-		-
(iii) In deposit accounts with original maturity of less than 3 months	-		-
(iv) In earmarked accounts (give details) (Refer Note (ii) below)	-		-
(d) Others (specify nature)	-		-
(e) Current investments considered as part of Cash and cash equivalents	-		-
Total	143.56		81.08

Place: Mumbai
Date: 30.05.2022



On behalf of the Board
FOR REMEDIUM LIFECARE LIMITED

[Signature]

VILAS LOKHANDE
WHOLE TIME DIRECTOR
DIN : 01228041